Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer

Breast Cancer Research

Volumn 11, Issue 3, 2009, Pages

  Foster, Fiona M ^a   Owens, Thomas W ^a   Tanianis Hughes, Jolanta ^a   Clarke, Robert B ^b   Brennan, Keith ^a   Bundred, Nigel J ^c   Streuli, Charles H ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; INHIBITOR OF APOPTOSIS PROTEIN; KI 67 ANTIGEN; LAPATINIB; SMALL INTERFERING RNA; SURVIVIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; HER2 PROTEIN, HUMAN; SIGNAL PEPTIDE; XIAP PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BT20 CANCER CELL LINE; BT474 CANCER CELL LINE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MDAMB468 CANCER CELL LINE; PROTEIN EXPRESSION; STAINING; APOPTOSIS; BIOLOGICAL MODEL; BIOSYNTHESIS; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 74049121619     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2328     Document Type: Article

References (55)

1. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007, 12:1543-1568. 10.1007/s10495-007-0087-3, 17573556.
2. Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003, 63:6815-6824.
3. Fulda S. Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther 2007, 7:1255-1264. 10.1586/14737140.7.9.1255, 17892425.
4. Morizane Y, Honda R, Fukami K, Yasuda H. X-linked inhibitor of apoptosis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/DIABLO. J Biochem (Tokyo) 2005, 137:125-132.
5. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 2001, 98:8662-8667. 37492, 11447297, 10.1073/pnas.161506698.
6. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006, 7:988-994. 1618369, 17016456, 10.1038/sj.embor.7400795.
7. Scott FL, Denault JB, Riedl SJ, Shin H, Renatus M, Salvesen GS. XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J 2005, 24:645-655. 548652, 15650747, 10.1038/sj.emboj.7600544.
8. Eckelman BP, Salvesen GS. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 2006, 281:3254-3260. 10.1074/jbc.M510863200, 16339151.
9. Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem 2000, 275:26661-26664.
10. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42. 10.1016/S0092-8674(00)00008-8, 10929711.
11. Byun SS, Yeo WG, Lee SE, Lee E. Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology 2007, 69:34-37. 10.1016/j.urology.2006.09.024, 17270609.
12. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, Moritz T, Laws HJ, Hanenberg H, Goebel U, Janka-Schaub GE, Mahotka C, Dilloo D. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 2007, 92:1043-1050. 10.3324/haematol.10675, 17640858.
13. Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 2007, 96:639-645. 10.1038/sj.bjc.6603616, 17285125.
14. Li M, Song T, Yin ZF, Na YQ. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin Med J (Engl) 2007, 120:469-473.
15. Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K, Takaha N, Ukimura O, Kawauchi A, Nonomura N, Bonavida B, Miki T. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 2007, 30:919-925.
16. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000, 6:1796-1803.
17. Ferreira CG, Valk P, Span SW, Jonker JM, Postmus PE, Kruyt FA, Giaccone G. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol 2001, 12:799-805. 10.1023/A:1011167113067, 11484955.
18. Seligson DB, Hongo F, Huerta-Yepez S, Mizutani Y, Miki T, Yu H, Horvath S, Chia D, Goodglick L, Bonavida B. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res 2007, 13:6056-6063. 10.1158/1078-0432.CCR-07-0960, 17947468.
19. Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, Imamura M, Ohki M, Inazawa J. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 2001, 61:6629-6634.
20. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267. 10.1016/j.cell.2006.05.030, 16814713.
21. Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007, 13:5995-6000. 10.1158/1078-0432.CCR-07-0729, 17947460.
22. LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006, 12:5231-5241. 10.1158/1078-0432.CCR-06-0608, 16951243.
23. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008, 27:6252-6275. 10.1038/onc.2008.302, 18931692.
24. Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, Korneluk RG. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 2000, 70:113-122. 10.1006/geno.2000.6364, 11087668.
25. Jaffer S, Orta L, Sunkara S, Sabo E, Burstein DE. Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma. Hum Pathol 2007, 38:864-870. 10.1016/j.humpath.2006.11.016, 17350670.
26. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005, 24:7381-7388. 10.1038/sj.onc.1208888, 16044155.
27. Tong QS, Zheng LD, Wang L, Zeng FQ, Chen FM, Dong JH, Lu GC. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 2005, 12:509-514.
28. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 2004, 11:309-316. 10.1038/sj.cgt.7700706, 15031723.
29. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, Morris SJ, Durkin JP, Lacasse EC. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004, 23:8105-8117. 10.1038/sj.onc.1207967, 15378029.
30. Fandy TE, Shankar S, Srivastava RK. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008, 7:60-69. 2474652, 18590557, 10.1186/1476-4598-7-60.
31. Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T, Lyerly HK, Devi GR. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther 2008, 7:38-47. 10.1158/1535-7163.MCT-07-0370, 18202008.
32. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693. 10.1016/j.cell.2007.10.037, 18022363.
33. Warnberg F, White D, Anderson E, Knox F, Clarke RB, Morris J, Bundred NJ. Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res 2006, 8:R21. 1557711, 16611371, 10.1186/bcr1395.
34. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000, 92:1185-1186. 10.1093/jnci/92.14.1185A, 10904098.
35. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH, Miller FR. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 2001, 65:101-110. 10.1023/A:1006461422273, 11261825.
36. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004, 64:3006-3008. 10.1158/0008-5472.CAN-04-0046, 15126334.
37. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 2004, 305:1471-1474. 10.1126/science.1098231, 15353805.
38. Wang L, Du F, Wang X. TNF-α induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703. 10.1016/j.cell.2008.03.036, 18485876.
39. Hussain SA, Palmer DH, Spooner D, Rea DW. Molecularly targeted therapeutics for breast cancer. BioDrugs 2007, 21:215-224. 10.2165/00063030-200721040-00002, 17628119.
40. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007, 254:165-177. 1986742, 17367921, 10.1016/j.canlet.2007.02.006.
41. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF, Hudson-Curtis BL, Gilmer TM. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007, 40:580-594. 10.1111/j.1365-2184.2007.00455.x, 17635524.
42. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005, 24:6213-6221. 10.1038/sj.onc.1208774, 16091755.
43. Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2006, 207:420-427. 10.1002/jcp.20588, 16419029.
44. Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003, 98:1377-1385. 10.1002/cncr.11656, 14508823.
45. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002, 62:5703-5710.
46. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ, Streuli CH. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 2002, 277:27643-27650. 10.1074/jbc.M108863200, 12011069.
47. Wang P, Gilmore AP, Streuli CH. Bim is an apoptosis sensor that responds to loss of survival signals delivered by epidermal growth factor but not those provided by integrins. J Biol Chem 2004, 279:41280-41285. 10.1074/jbc.C400248200, 15292207.
48. Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A, Diermeier S. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007, 40:488-507. 10.1111/j.1365-2184.2007.00449.x, 17635517.
49. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005, 23:2460-2468. 10.1200/JCO.2005.00.661, 15710948.
50. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000, 6:127-134.
51. Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005, 65:11018-11025. 10.1158/0008-5472.CAN-05-0491, 16322251.
52. Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006, 94:253-258. 10.1038/sj.bjc.6602932, 16421596.
53. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006, 17:597-604. 10.1093/annonc/mdj121, 16403812.
54. Angell H. A study into the potential role of Survivin localization in resistance to drug-induced apoptosis. Biosci Horiz 2008, 1:85-91.
55. Ziegler DS, Wright RD, Kesari S, Lemieux ME, Tran MA, Jain M, Zawel L, Kung AL. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest 2008, 118:3109-3122. 2491457, 18677408, 10.1172/JCI34120.